Zenas BioPharma Statistics

Total Valuation

Zenas BioPharma has a market cap or net worth of $2.11 billion. The enterprise value is $1.82 billion.

Market Cap	2.11B
Enterprise Value	1.82B

Important Dates

The last earnings date was Wednesday, November 12, 2025, before market open.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Zenas BioPharma has 53.68 million shares outstanding. The number of shares has increased by 1,252.33% in one year.

Current Share Class	53.68M
Shares Outstanding	53.68M
Shares Change (YoY)	+1,252.33%
Shares Change (QoQ)	+0.70%
Owned by Insiders (%)	1.26%
Owned by Institutions (%)	52.18%
Float	31.80M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	110.11
Forward PS	n/a
PB Ratio	8.46
P/TBV Ratio	10.76
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	121.59
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.66, with a Debt / Equity ratio of 0.00.

Current Ratio	5.66
Quick Ratio	5.57
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -68.33% and return on invested capital (ROIC) is -43.91%.

Return on Equity (ROE)	-68.33%
Return on Assets (ROA)	-33.72%
Return on Invested Capital (ROIC)	-43.91%
Return on Capital Employed (ROCE)	-72.59%
Revenue Per Employee	$115,385
Profits Per Employee	-$1.46M
Employee Count	130
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

In the past 12 months, Zenas BioPharma has paid $244,000 in taxes.

Income Tax	244,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +300.20% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+300.20%
50-Day Moving Average	30.22
200-Day Moving Average	16.51
Relative Strength Index (RSI)	61.91
Average Volume (20 Days)	335,438

Short Selling Information

The latest short interest is 4.61 million, so 8.58% of the outstanding shares have been sold short.

Short Interest	4.61M
Short Previous Month	4.77M
Short % of Shares Out	8.58%
Short % of Float	14.49%
Short Ratio (days to cover)	8.22

Income Statement

In the last 12 months, Zenas BioPharma had revenue of $15.00 million and -$189.90 million in losses. Loss per share was -$4.53.

Revenue	15.00M
Gross Profit	-146.50M
Operating Income	-195.70M
Pretax Income	-189.66M
Net Income	-189.90M
EBITDA	-195.62M
EBIT	-195.70M
Loss Per Share	-$4.53

Full Income Statement

Balance Sheet

The company has $290.88 million in cash and $798,000 in debt, giving a net cash position of $290.09 million or $5.40 per share.

Cash & Cash Equivalents	290.88M
Total Debt	798,000
Net Cash	290.09M
Net Cash Per Share	$5.40
Equity (Book Value)	196.43M
Book Value Per Share	4.65
Working Capital	244.22M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$158.47 million and capital expenditures -$92,000, giving a free cash flow of -$158.57 million.

Operating Cash Flow	-158.47M
Capital Expenditures	-92,000
Free Cash Flow	-158.57M
FCF Per Share	-$2.95

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-1,304.64%
Pretax Margin	-1,264.37%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Zenas BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,252.33%
Shareholder Yield	-1,252.33%
Earnings Yield	-8.98%
FCF Yield	-7.50%

Dividend Details

Analyst Forecast

The average price target for Zenas BioPharma is $40.00, which is 1.57% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$40.00
Price Target Difference	1.57%
Analyst Consensus	Strong Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	114.06%
EPS Growth Forecast (5Y)	-33.59%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Zenas BioPharma has an Altman Z-Score of -0.86 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.86
Piotroski F-Score	1